Abnormal daytime somnolence, "sleep attacks", and antiparkinson drugs;Pharmacologie: Somnolence diurne anormale, « attaques de sommeil » et médicaments antiparkinsoniens

Revue Neurologique

Volumn 157, Issue 10, 2001, Pages 1313-1323

  Rascol, O ^a   Ferreira, J ^a   Montastruc, J L ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CABERGOLINE; ENTACAPONE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE;

CLINICAL TRIAL; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; HUMAN; PHARMACOEPIDEMIOLOGY; PHASE 4 CLINICAL TRIAL; PHENOMENOLOGY; REVIEW; SLEEP DISORDER; SOMNOLENCE; CHEMICALLY INDUCED DISORDER; CIRCADIAN RHYTHM; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; PARKINSON DISEASE; WAKEFULNESS;

ANTIPARKINSON AGENTS; CIRCADIAN RHYTHM; CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; PARKINSON DISEASE; WAKEFULNESS;

EID: 0035164048     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Ropinirole for the treatment of early Parkinson's disease
2. Neurobiologie du cycle veille-sommeil
3. Treatment of Parkinson's disease with pergolide: A double-blind study
4. Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect
5. L-Dopa-induced sedation: A double blind crossover controlled study versus triazolam and placebo in healthy volunteers
6. Letter to the editor
7. Hallucinations, REM sleep, and Parkinson's disease. A medical hypothesis
8. Is excessive daytime sleepiness in Parkinson's disease really related to poor sleep quality ? An objective study in 47 patients
9. Suppression of REM rebound by pergolide
10. Reversal of sleep disturbances in Parkinson's disease by antiparkinsonian therapy: A preliminary study
11. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
12. Pergolide monotherapy in the treatment of early PD: A randomized, controlled study
13. Behavioural manifestations elicited by apomorphine, influence of the route of administration
14. Dopamine receptors and sleep induction in man
15. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease
16. Daily somnolence and night sleep in Parkinson's disease: Role of treatment and disease severity
17. Daytime sleepiness and antiparkinsonian treatment
18. Suppression of REM and delta sleep by apomorphine in man: A dopamine mimetic effect
19. Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice
20. Neurobiology and segmental neurology of sleep
21. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys
22. An estimate of the incidence of depression in idiopathic Parkinson's disease
23. Sleep attacks in Parkinson's disease: Polysomnographic recordings
24. Sleep disorders and sleep effect in Parkinson's disease
25. Somnolence as an adverse drug reaction of antiparkinsonian drugs: A meta-analysis of published randomised placebo-controlled trials
26. "Sleep attacks" and Parkinson's disease treatment
27. "Sleep attacks" as an adverse drug reaction of levodopa monotherapy
28. Ropinirole-induced sedation: A randomised placebo controlled study in healthy volunteers
29. Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients
30. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
31. Sleep episodes in Parkinson's disease: A wake-up call
32. Relationships among pain, depression, and sleep alterations in Parkinson's disease
33. Pramipexole-induced somnolence and episodes of daytime sleep
34. Letter to the editor
35. Sleep attacks after acute administration of apomorphine
36. Driver sleepiness and sleep disorders, with particular reference to Parkinson's disease
37. Parallel double-blind study of pergolide in Parkinson's disease
38. Madopar HBS in Parkinson patients with nocturnal akinesia
39. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats
40. Excessive daytime sleepiness and sudden onset sleep in Parkinson's disease: A survey from 18 canadian movement disorders clinics
41. Parkinson's disease in the elderly: Response to and optimal spacing of night time dosing with levodopa
42. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease
43. The night time problems of Parkinson's disease
44. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy
45. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat
46. Dopaminergic stimulation enhances the utilization of noradrenaline in the central nervous system
47. Sudden sleep attacks and antiparkinsonian drugs: A pilot prospective pharmacoepidemiological study
48. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat
49. Sleep disruption in the course of chronic levodopa therapy: An early feature of the levodopa psychosis
50. 5-Hydroxytryptamine and noradrenaline uptake inhibition: Studies on sleep in man
51. Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor
52. Effects of drugs on sleep
53. A multicenter double-blind placebocontrolled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
54. Continuous dopamine-receptor stimulation in early Parkinson's disease
55. Waking up to sleep episodes in Parkinson's disease
56. A comparative study of daytime sleepiness within Parkinson's isease patients treated with cabergoline, pramipexole, and levodopa
57. Sleep attacks in two Parkison's Disease patients taking ropinirole
58. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study
59. Entacapone improves motor fluctuations in levodopatreated Parkinson's disease patients
60. Drugs and the sleep-wakefulness continuum
61. The apomorphine test for diagnosis of parkinsonian syndrome
62. Efficacy, safety, and tolerance of the nonergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study
63. Sleep attacks in Parkinson's disease
64. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial
65. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
66. Sleep disruption, daytime somnolence and "sleep attacks" in Parkinson's disease: A clinical survey in PD patients and age-matched healthy volunteers
67. Falling asleep wilst driving: Are drivers aware of prior sleepiness?
68. A survey of antidepressant drug use in Parkinson's disease
69. Nonergot dopamine agonist-induced sleep attacks
70. Daytime sleepiness in Parkinson's disease
71. Sleep attacks (sleep episodes) with pergolide
72. Ropinirole for the treatment of early Parkinson disease: A 12-month experience
73. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
74. Sleep disorders, pain, and depression in Parkinson's disease
75. Sleep disorders in Parkinson's disease
76. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease
77. Five years treatment of Parkinson's Disease with levodopa
78. A community-based study of sleep disorders in patients with parkinson's disease
79. Excessive daytime sleepiness and sleep benefit in Parkinson's Disease: A community based study
80. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease
81. Sustained-release levodopa in parkinsonian patients with nocturnal disabilities
82. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring
83. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease
84. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
85. A double-blind, placebocontrolled, randomized, multi-center study of pramipexole in advanced Parkinson's disease